Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia
Open Access
- 14 February 2020
- journal article
- review article
- Published by Springer Nature in World Journal of Urology
- Vol. 38 (11) , 2771-2779
Abstract
Purpose: To review the role of a persistent prostatic inflammatory status (PIS) in the development and progression of benign prostatic hyperplasia (BPH) associated with lower urinary tract symptoms (LUTS) and which medical therapies approved for LUTS/BPH may reduce persistent PIS. Methods: Literature search in PubMed up to July 2019. Results: The cause of histologically defined persistent PIS or chronic prostatic inflammation is multifactorial. It is evident in many men with LUTS/BPH, particularly in older men and in men with a large prostate volume or more severe (storage) LUTS. Additionally, persistent PIS is associated with an increased risk of acute urinary retention and symptom worsening. Of medical therapies approved for LUTS/BPH, the current evidence for a reduction of persistent PIS is greatest for the hexanic extract of Serenoa repens (HESr). This treatment relieves LUTS to the same extent as α1-adrenoceptor antagonists and short-term 5α-reductase inhibitors. Limited evidence is available on the effect of other mainstream LUTS/BPH treatments on persistent PIS. Conclusions: Persistent PIS plays a central role in both the development and progression of LUTS/BPH. In men with LUTS/BPH who have a high chance of harbouring persistent PIS, HESr will not only improve LUTS, but also reduce (underlying) inflammation. Well-designed clinical studies, with a good level of evidence, are required to better evaluate the impact of BPH/LUTS medical therapies on persistent PIS.Keywords
Funding Information
- Pierre Fabre Pharma Italy
This publication has 62 references indexed in Scilit:
- Lipidosterolic Extract of Serenoa Repens Modulates the Expression of Inflammation Related-Genes in Benign Prostatic Hyperplasia Epithelial and Stromal CellsInternational Journal of Molecular Sciences, 2013
- Correlation between benign prostatic hyperplasia and inflammationCurrent Opinion in Urology, 2013
- Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia Patients: Orchestrated by Chronic Prostatic Inflammation and Prostatic Calculi?Urologia Internationalis, 2012
- Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome‐associated prostate alterations: An experimental study in the rabbitThe Prostate, 2012
- The Effect of Intraprostatic Chronic Inflammation on Benign Prostatic Hyperplasia TreatmentKorean Journal of Urology, 2010
- Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysisThe Prostate, 2009
- Histologic Influence of Doxazosin and Finasteride in Benign Prostatic Hyperplasia Accompanying Chronic InflammationUrologia Internationalis, 2008
- The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE TrialEuropean Urology, 2008
- Examination of the Relationship Between Symptoms of Prostatitis and Histological Inflammation: Baseline Data From the REDUCE Chemoprevention TrialJournal of Urology, 2007
- Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia?BJU International, 2007